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TO THE EDITOR
Most effective therapeutic interventions
in mast cell (MC)-driven diseases focus
on the inhibition of histamine-mediated
processes by blocking the histamine
1-receptor with antihistamines (Hore
et al., 2005; Monroe, 2005). Other
therapeutic possibilities to control his-
tamine- and other MC-mediator-related
symptoms include the application of
cromoglycate, anti-inflammatory ster-
oids, or calcineurin inhibitors, all of
which are inhibitors of MC degranula-
tion. Many receptor-mediated signal
transduction processes, such as those
involved in immunoglobulin E (IgE)-
receptor (FceRI)-dependent MC activa-
tion with subsequent degranulation, are
regulated in lipid rafts in the cell
membrane (Holowka and Baird, 2001;
Heneberg et al., 2006). Lipid rafts are
assemblies of phospholipids, glyco-
lipids, and cholesterol together with
raft proteins, forming localized mem-
brane microdomains. The specific com-
position and dynamics of these lipid
rafts enables the productive interaction
of raft proteins, such as FceRI. There-
fore, we considered it feasible to target
rafts of human MCs with lipid-like small
molecule drugs to prevent FceRI-de-
pendent MC activation. A candidate
raft-modulating drug is miltefosine
(hexadecylphosphocholine), an alkyl-
phospholipid already approved for the
treatment of breast cancer metastasis
and leishmaniasis. Miltefosine is a
derivative of cell membrane plasmalo-
gen phospholipids, which are enriched
in rafts containing FceRI (Surviladze
et al., 2007), and there is a significant
body of evidence demonstrating the
inhibition of signal transduction path-
ways at the level of the cell membrane
by miltefosine (Arthur and Bittman,
1998). Miltefosine has also been shown
to be taken up by cells in a raft-
dependent fashion (van der Luit et al.,
2007), suggesting that it has an affinity
to lipid raft microdomains and Gros-
man (1991) reported the inhibition by
miltefosine of histamine release from
isolated rat MCs triggered with calcium
ionophore A23187 and compound
48/80.
Hypothesizing that miltefosine may
act as an inhibitor of IgE-dependent
human MC activation, we first mea-
sured mediator release from skin MCs
in response to anti-IgE after pretreat-
ment with miltefosine in vitro. To this
end, MCs were isolated from human
skin as previously described (Artuc
et al., 2002, 2006). The cells were then
incubated for different times with dif-
ferent concentrations of miltefosine.
Subsequently, cells were stimulated
with mouse anti-IgE (Calbiochem,
Darmstadt, Germany) and supernatants
were analyzed for the MC-products
histamine, arachidonic acid metabo-
lites (prostaglandin D2; PGD2), and
cytokines (tumor necrosis factor; TNF).
Quantification of histamine levels was
achieved using an automated hista-
mine-analyzer system (Borgwaldt Tech-
nik, Hamburg, Germany; Siraganian,
1975). The release of PGD2 was deter-
mined 30 minutes after stimulation
using an enzyme immunoassay (Cay-
man Chemical, Ann Arbor, MI; Wang
et al., 2006) and TNF release by human
MCs was measured 24 hours after
anti-IgE stimulation, using a human
TNF immunoassay kit (R&D Systems,
Wiesbaden, Germany; Guhl et al.,
2005). Interestingly, miltefosine dose-
dependently inhibited anti-IgE-induced
histamine release with a maximal effect
at 25 mM. Even short preincubation
times of as little as 10 minutes lead to
maximal inhibitory effects (Figure 1a).
Similar results were obtained using
preincubation times of 30 and 60 min-
utes (data not shown). In addition,
miltefosine also lead to a dose depen-
dent inhibition of TNF release. The
maximal inhibitory effect was 450%
and resulted from the preincubation
with miltefosine for 10 minutes at
25 mM (Figure 1c). In contrast, preincu-
bation with miltefosine did not result in
any inhibition of PGD2 release in
human MCs (Figure 1b).
In addition to FceRI-dependent med-
iator release, we also assessed the
effects of miltefosine on FceRI-indepen-
dent MC activation pathways. MCs
were stimulated with 30mM substance
P (Sigma-Aldrich, Steinheim, Ger-
many), which induces histamine re-
lease from human MCs primarily via
stimulation of the neurokinin 1 recep-
tor. Surprisingly, inhibition of substance
P-induced histamine release by milte-
fosine was similar to the effect seen on
anti-IgE-induced MC degranulation,
that is, miltefosine inhibited histamine
release dose dependently (Figure 1d),
but not time dependently. Inhibition of
histamine release after a preincubation
time of 10 minutes (Figure 1d) was
equal to the inhibition obtained after
preincubation times of 30 and 60 min-
utes (data not shown).
To confirm the potent inhibitory
effect of miltefosine on IgE-dependent
human MC activation and mediator
release in vivo, five selected allergic
volunteers were subjected to a topical
application of 6% miltefosine solution
(two drops on 16 cm2) on one inner
forearm and saline control solution on
the contralateral forearm in a double-
blinded fashion. Two hours later, stan-
dard skin-prick tests using solutions
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Abbreviations: IgE, immunoglobulin E; MC, mast cell; PGD2, prostaglandin D2; TNF, tumor necrosis
factor
with their known allergens (2 house
dust mites, 2 grass mix, 1 cat hair)
as well as positive (histamine) and
negative (saline) controls were per-
formed at the pretreated areas. Devel-
oping wheals and erythemata were
examined macroscopically by measur-
ing verticular and perpendicular dia-
meters (Niederberger et al., 2001). Most
interestingly, diameters of wheals and
erythemata induced by allergen were
significantly smaller (P¼ 0.023 and
P¼0.023) in the regions pretreated
with miltefosine as compared to saline
pretreated control sites (Figure 2a and
c). This reduction of wheal diameters
was observed during the whole time
course from minute 15 to minute 30
after skin-prick testing. In contrast,
neither the diameters of histamine-
induced wheals nor the diameters of
histamine-induced erythemata were
reduced significantly by miltefosine
pretreatment as compared to the saline-
treated control areas (Figure 2b and d).
In summary, we show that miltefo-
sine can inhibit the activation,
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Figure 1. Miltefosine inhibits human MC activation and mediator release in vitro. After isolation of MCs from human skin, cells were incubated for 10minutes with
different concentrations of miltefosine (5mM , 10mM , 20mM , 25mM’, or vehicle PBS/DMSO& serving as a control). Subsequently, MCs were stimulated with
(a–c) anti-IgE or (d) substance P. Supernatants were analyzed for release of (a,d) histamine 30minutes post stimulation using an automated histamine-analyzer system,
(b) TNF release 24hours after stimulation using a human TNF immunoassay kit, and (c) prostaglandin D2 (PGD2) 30 minutes post stimulation employing an enzyme
immunoassay. Mediator release after anti-IgE or substance P stimulation without miltefosine preincubation (first bars) was set as 100%. Real values of these control groups
were (a) 21.2±3.8 ng histamine/40,000 cells, (c) 207.0±13.6 pg TNF/500,000 cells, (b) 2.7±0.6ng PGD2/500,000 cells, and (d) 15.5±1.1ng histamine P/40,000 cells.
Mediator release in all other settings (miltefosine, PBS/DMSO preincubation) is presented as percent of these values. Basal histamine release was subtracted from the
values of histamine release after stimulation. It varied around 5–7% of total histamine content of the MCs (76.0±8.3ng/40,000 cells). Data are shown as mean±SEM of
3–5 separate experiments, *Po0.05, **Po0.01 miltefosine compared to vehicle preincubation (two-tailed Student’s t-test for paired samples).
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Figure 2. Miltefosine inhibits mast cell-driven responses in vivo. Five allergic volunteers were subjected to
standard skin-prick testing with solutions containing (a,c) their known allergens, (b,d) histamine, and negative
(saline) controls (no reactions, data not shown) on both forearms. Using a double blind, placebo-controlled
approach, one forearm of each test person was pretreated with topical 6% miltefosine solution (K), whereas
the contralateral side was pretreated with placebo saline solution (J), both for 2hours prior to skin-prick
testing. The course of developing (a,b) wheals and (c,d) erythemata was assessed macroscopically by measuring
the biggest and perpendicular diameter. Subsequently, the sum of both diameters was divided by two. Data are
presented as mean±SEM, *Po0.05 for comparing area under the curve (ANOVA, Fisher’s PLSD).
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Miltefosine inhibits mast cell activation
degranulation, and mediator release of
human MCs in vitro, and that topical
treatment with a 6% miltefosine solu-
tion may inhibit IgE-dependent human
MC activation in vivo. The in vitro MC-
stabilizing effect of miltefosine appears
not to be limited to IgE-dependent
activation nor to histamine release but
also comprises alternative IgE-indepen-
dent activation pathways and release of
cytokines. In addition, we provide
proof-of-concept that miltefosine also
inhibits IgE-dependent MC-mediated
inflammatory responses in vivo.
These results indicate that agents
with raft disrupting properties, such
as miltefosine, have the potential as
new therapeutics for the treatment of
MC-driven diseases and we suggest
that clinical studies should be under-
taken to confirm the efficacy of milte-
fosine and related substances on
MC-related effects. In addition, future
investigations will need to address
the complexity of cellular pathways
involved in their inhibition of MC
activation and mediator release. All
examinations were performed after in-
stitutional approval and in adherence
to the Declaration of Helsinki. All
volunteers gave their written informed
consent.
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TO THE EDITOR
Thymic stromal lymphopoietin (TSLP)
appears to be a master switch for
T helper (Th)2 allergic inflammation
such as atopic dermatitis (AD) and
asthma (Liu, 2006). TSLP expression is
increased in keratinocytes in skin le-
sions of patients with AD (Soumelis
et al., 2002), and various mouse models
have established a link between TSLP
expression and the pathogenesis of AD
(Li et al., 2005, 2006; Yoo et al., 2005).
Abbreviations: AD, atopic dermatitis; LN, lymph node; Th2, T helper 2; TSLP, thymic stromal
lymphopoietin; WT, wild-type
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Induction of TSLP Expression in Keratinocytes
